Combination Therapy for Patients Hospitalized with COVID-19

摘要

In a randomized trial, baricitinib plus remdesivir shortened recovery time by 1 day compared with remdesivir alone. Patients with severe COVID-19 have dys-regulated inflammatory responses and elevated cytokine levels. Baricitinib, a Janus kinase inhibitor, blocks cytokine signaling and may also have anti-SARS-CoV-2 activity. To assess whether adding baricitinib to remdesivir improves outcomes, 1033 patients hospitalized with COVID-19 were randomized to receive baricitinib plus remdesivir (combination therapy) or remdesivir alone in the ACTT-2 trial.